Toggle light / dark theme

Terahertz imaging maps spatial chirality in materials with 100-micrometer resolution

In nature, there exist structures that are mirror images of each other but cannot be perfectly superimposed. These are known as chiral objects, derived from the Greek word for “hand,” since left and right hands share the same relationship. Although similar in structure, chiral molecules exhibit different behaviors, and chirality is central to life itself. DNA has a twisted chiral structure, and living organisms prefer one handedness over the other. This distinction is equally important in drug design, materials science, and nanotechnology.

One way to distinguish chiral molecules is by measuring their response to circularly polarized light in the terahertz (THz) region. THz waves lie between microwaves and infrared light and are especially sensitive to subtle collective motions and twisting structures in materials. However, conventional THz measurements average the signal across an entire sample, making it impossible to determine how chirality varies across different locations.

Now, researchers from Chiba University, Japan, and Tohoku University, Japan, have shown that this limitation can be overcome, allowing chirality to be visualized as two-dimensional images, much like creating a map of chirality across a material. The work appears in ACS Photonics.

Proteins can be selectively controlled with radio waves

In a significant advance in biological quantum sensing, a research team led by the Technical University of Munich (TUM) has discovered and tested a new mechanism of action in which proteins can be controlled with radio waves. In doing so, they influence a sensitive quantum state known as spin and make it visible via light. In the future, such findings could help detect and even direct biochemical processes in cells simply from the outside using radio waves.

Until now, quantum sensing has primarily been known from solid-state materials such as diamonds with deliberately introduced tiny defects. The researchers are now transferring this principle to proteins —biological molecules that can be genetically produced and specifically tailored. In the future, this could allow quantum sensors to be built directly into cells or tissue.

These protein-based sensors are potentially particularly well suited for biosensing—that is, for imaging living cells, tissues, or organs. In theory, they sit directly where measurement is needed, making them suitable for studies in organisms—unlike bulky solid-state sensors.

First human SMUG1 atomic snapshots reveal how cells repair DNA

Researchers have captured the first atomic structures of human SMUG1, an enzyme that helps cells repair damaged DNA. The findings provide new insight into how cells recognize and remove harmful DNA bases, and may support future efforts to develop drugs that target this DNA repair pathway.

“These structures give us the first detailed view of how human SMUG1 engages damaged DNA and carries out the first steps of repair,” says professor Pål Stenmark, who led the study.

DNA is constantly damaged by normal processes in our cells, as well as by environmental factors and cancer treatments. If the damage is not repaired, it can lead to permanent mutations.

Deep brain stimulation boosts myelination and shifts brain networks linked to depression

Researchers from the Icahn School of Medicine at Mount Sinai have uncovered the first direct evidence that deep brain stimulation (DBS) can remodel white matter pathways in the brain and alter communication across large-scale neural networks, revealing a previously unrecognized mechanism that may explain how the therapy helps patients recover from severe depression. The study, published June 1 in Nature Neuroscience, provides critical insight into the biological basis of DBS, an emerging therapy for treatment-resistant depression and other neuropsychiatric disorders.

Deep brain stimulation, approved by the U.S. Food and Drug Administration to treat essential tremor, Parkinson’s disease, epilepsy, and obsessive-compulsive disorder, is a neurosurgical procedure involving placement of a neurostimulator (sometimes referred to as a “brain pacemaker”), which sends high-frequency electrical impulses through implanted electrodes deep in the brain to specific areas responsible for the symptoms of each disorder.

Although DBS has shown sustained clinical benefit for many patients with severe depression who do not respond to medications, psychotherapy, and electroconvulsive therapy, the mechanisms underlying its therapeutic effects have remained poorly understood.

Stress Can Literally Make You Lose Your Direction, According to New MRI Evidence

People under stress may find it harder to orient themselves in space, and researchers in Bochum have identified a possible reason why. The stress hormone cortisol appears to interfere with the brain system that helps people navigate. It weakens the activity of grid cells, which are important for

The Deliverome Project

Congratulations to the team of on their launch! This new Focused Research Organization aims to “building an open atlas of the human surfaceome — abundance, specificity, internalization, and routing — to scale targeted delivery beyond the liver.” I’m excited to see the impact this FRO has, particularly on the gene therapy world!


An open receptor atlas for targeted delivery beyond the liver, integrating abundance, specificity, internalization, and routing.

New RNA sequencing method reveals hidden layer of immune system control

Researchers at University Medical Center Utrecht have uncovered a previously underappreciated mechanism that helps immune cells to respond rapidly to infections. Using advanced long-read RNA sequencing, the team shows that alternative RNA splicing, which means how genes are edited into different messenger RNA variants, plays a central role in shaping immune responses. The findings provide new insights into immune-mediated diseases (such as infections, rheumatoid arthritis and lupus) and may open the door to more targeted therapies.

The study, published in Nature Communications, focused on monocytes, a type of innate immune cell that acts as a first responder to pathogens. When these cells encounter bacterial components such as cell wall components, they must quickly adapt to mount an effective defense. While earlier research has largely examined changes in overall gene expression, this study zoomed in on RNA isoforms, the different transcript variants that a single gene can produce.

Using long-read RNA sequencing, researchers at the Center for Translational Immunology (University Medical Center Utrecht, the Netherlands) generated a comprehensive map of full-length RNA transcripts in human monocytes before and after activation. They identified more than 24,000 isoforms, of which the majority have never been described, revealing a previously hidden layer of molecular complexity.

Deep brain stimulation induces white matter remodeling and functional changes to brain-wide networks

In a nonhuman primate model, Fujimoto et al. show that deep brain stimulation promotes white matter remodeling and reorganizes brain-wide functional networks, detailing a mechanism through which this neuromodulation therapy may treat depression.

BREAKTHROUGH CHOLESTEROL CURE Lowers LDL For Life

New LDL Drug Could Cure Heart Disease. Eli Lilly published Phase 1 data in the New England Journal of Medicine showing that a single IV infusion of a gene editing therapy called VERVE-102 lowered LDL cholesterol permanently. Well… the effect held for at least 18 months. Longevity Twitter immediately called it the cure for heart disease. The science is real. The hype is getting ahead of what the paper actually says. This episode walks through the Phase 1 Heart-2 trial — the data, the base-editing mechanism (which is NOT CRISPR), the one safety event nobody’s talking about, and how Eli Lilly’s CEO is publicly thinking about pricing a one-and-done cure.

HUME BODY POD DISCOUNT UP TO 50% OFF:
Code: LSN20
https://humehealth.com/pages/hume-bod… Latte: https://longevitylatte.shop TIMESTAMPS 0:00 — Cold Open 1:41 — Sponsor: Hume Body Pod 2:53 — Intro: The Cholesterol Paradox 4:48 — How Statins Work 5:36 — PCSK9 Targeting 7:38 — How VERVE-102 Works 9:16 — The Results 12:16 — Other Drugs and Pricing 15:12 — Natural Alternatives 17:42 — Other One and Done Drugs 18:40 — Longevity Latte SOURCES & LINKS NEJM paper (Vafai, Täubel, Patel, Kathiresan et al.): https://www.nejm.org/doi/full/10.1056… Eli Lilly press release on Phase 1 Heart-2 data: https://www.prnewswire.com/news-relea… ClinicalTrials.gov Heart-2 trial entry (NCT06164730): https://clinicaltrials.gov/study/NCT0… Verve Therapeutics FDA Fast Track designation announcement: https://vervetx.gcs-web.com/news-rele… Cohen and Hobbs 2006 NEJM paper (the foundational PCSK9 loss-of-function discovery): https://www.nejm.org/doi/abs/10.1056/.… Dave Ricks (Eli Lilly CEO) on Cheeky Pint with Patrick and John Collison: • Dave Ricks, CEO of Eli Lilly, on GLP-1s an… FOURIER trial (evolocumab cardiovascular outcomes): https://www.nejm.org/doi/full/10.1056… ODYSSEY OUTCOMES trial (alirocumab cardiovascular outcomes): https://www.nejm.org/doi/full/10.1056… PCSK9 LoF and diabetes (Mendelian randomization, Lancet Diabetes & Endocrinology): https://www.thelancet.com/journals/la… PCSK9 inhibition and diabetes risk review: https://pmc.ncbi.nlm.nih.gov/articles… StatPearls overview of PCSK9 inhibitors: https://www.ncbi.nlm.nih.gov/books/NB… Sardinia cholesterol paradox study: https://pmc.ncbi.nlm.nih.gov/articles… Statin pleiotropic effects review (mevalonate pathway): https://www.ncbi.nlm.nih.gov/pmc/arti… Berberine as a nature-made PCSK9 inhibitor review: https://www.ncbi.nlm.nih.gov/pmc/arti… Berberine for dyslipidaemias meta-analysis: https://pubmed.ncbi.nlm.nih.gov/30466… Pomegranate juice, carotid IMT, and LDL oxidation (Aviram 3-year study): https://www.clinicalnutritionjournal… LATEST EXCLUSIVE INTERVIEW: [Ariel Garten / Muse headset interview YouTube URL] ABOUT LONGEVITY SCIENCE NEWS Longevity Science News covers the latest breakthroughs in anti-aging research, regenerative medicine, longevity biotech, and the science of extending human healthspan and lifespan. Hosted by Emmett Short. Disclaimer: This video is for educational and informational purposes only and does not constitute medical advice. Consult a qualified clinician before making health or treatment decisions. EXCLUSIVE INTERVIEWS & BONUS CONTENT Patreon: https://patreon.com/u29506604?utm_med… YT Membership: / @longevitysciencenews PRODUCTION CREDITS Executive Producer – Keith Comito Host, Producer, Writer – Emmett Short.

Longevity Latte:
https://longevitylatte.shop.

TIMESTAMPS
0:00 — Cold Open.
1:41 — Sponsor: Hume Body Pod.
2:53 — Intro: The Cholesterol Paradox.
4:48 — How Statins Work.
5:36 — PCSK9 Targeting.
7:38 — How VERVE-102 Works.
9:16 — The Results.
12:16 — Other Drugs and Pricing.
15:12 — Natural Alternatives.
17:42 — Other One and Done Drugs.
18:40 — Longevity Latte.

SOURCES \& LINKS
NEJM paper (Vafai, Täubel, Patel, Kathiresan et al.): https://www.nejm.org/doi/full/10.1056
Eli Lilly press release on Phase 1 Heart-2 data: https://www.prnewswire.com/news-relea
ClinicalTrials.gov Heart-2 trial entry (NCT06164730): https://clinicaltrials.gov/study/NCT0
Verve Therapeutics FDA Fast Track designation announcement: https://vervetx.gcs-web.com/news-rele
Cohen and Hobbs 2006 NEJM paper (the foundational PCSK9 loss-of-function discovery): https://www.nejm.org/doi/abs/10.1056/.
Dave Ricks (Eli Lilly CEO) on Cheeky Pint with Patrick and John Collison: • Dave Ricks, CEO of Eli Lilly, on GLP-1s an…

/* */